T. Ho

发表

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.

Amanda M Li, A. Kernytsky, D. Altshuler, 2020, The New England journal of medicine.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

B. Gilks, J. Ledermann, A. Gutin, 2015, British Journal of Cancer.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

E. Kohn, D. Bowtell, A. Oza, 2017, Clinical Cancer Research.

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

K. Gelmon, S. Domchek, U. Matulonis, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

B. Gilks, J. Ledermann, A. Gutin, 2018, British Journal of Cancer.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

James X. Sun, Roman Yelensky, Zhongwu Lai, 2017, Oncotarget.

Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations inBRCA1orBRCA2are biologically similar and sensitive to PARP inhibition

James X. Sun, R. Yelensky, J. Ledermann, 2015 .

Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

A. Oza, J. Ledermann, U. Matulonis, 2015, Cancer.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

E. Kohn, J. Taube, E. Swisher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells

S. Grupp, S. Sheth, M. Cappellini, 2020 .

Outcomes and endpoints in cancer trials: bridging the divide.

Katherine Karakasis, Deborah Collyar, Ian F Tannock, 2015, The Lancet. Oncology.

Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.

T. Powles, A. Gupta, P. Dennis, 2017 .

Candidate predictive biomarkers for response to olaparib in advanced gastric cancer (AGC).

J. Barrett, Y. Bang, D. Hodgson, 2016 .

Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404).

E. Kohn, L. Minasian, S. Lipkowitz, 2016 .